4.4 Article

Consistent MYC and FLT4 Gene Amplification in Radiation-Induced Angiosarcoma But Not in Other Radiation-Associated Atypical Vascular Lesions

期刊

GENES CHROMOSOMES & CANCER
卷 50, 期 1, 页码 25-33

出版社

WILEY-BLACKWELL
DOI: 10.1002/gcc.20827

关键词

-

资金

  1. NIH [P01 CA47179, RC2 CA148260, P50 CA140146]
  2. NCI-ASCO Cancer Foundation
  3. Shuman Fund for GIST Research
  4. NATIONAL CANCER INSTITUTE [RC2CA148260, P01CA047179, P50CA140146] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Angiosarcoma (AS) is a distinct group of sarcomas characterized by upregulation of vascular-specific receptor tyrosine kinases, including TIE1, KDR, TEK, and FLT1. In keeping with the clinical heterogeneity, gene-expression profiling distinguishes two AS genomic clusters, which correlate with anatomical location and prior exposure to radiation. Furthermore, a high percentage of secondary AS, but not primary AS, shows distinct 8q24 chromosomal gains, due to MYC amplification. In this study, we mined the transcriptional output of 10 secondary and 11 primary AS to better define the dichotomy in the pathogenesis of these two clinical subsets. The oncogenic role of MYC was investigated further in secondary AS as well as in radiation-induced atypical vascular lesions (AVL) and other radiation-associated sarcomas. High-level MYC amplification was found in 100% of secondary AS, but in none of the AVL or other radiation-associated sarcomas. Coamplification of FLT4 (encoding VEGFR3) was identified in 25% of secondary AS, but not in other types. Our findings reinforce the distinct pathogenesis of AS subtypes, with MYC amplification being an early, but necessary event in secondary AS. Secondary genetic hits, such as FLT4 gene coamplification or KDR mutations, may play a role in tumor progression as well as potential therapeutic targeting. (C) 2010 Wiley-Liss, Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据